Featured Research Search Results
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Treatment study for people with metastatic, triple-negative breast cancer
Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT05929768
Treatment
Treatment study for early-stage triple-negative breast cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT05720039
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
Clinicaltrials.gov identifier:
NCT02693535
Treatment
Cancer treatment study for people with advanced solid tumors
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)
Sponsored By
